TMFBiologyFool

Article

TMFBiologyFool published an article 3:16 PM

The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)

Two deaths after patients take Eli Lilly's Zyprexa Relprevv.

Article

TMFBiologyFool published an article 4:11 PM

Abbott Loves Abbott Laboratories Stock

Company announces a $3 billion buyback.

Article

TMFBiologyFool published an article 7:00 PM

White Collar Criminals Love Biotech Stocks

It's easy to see why.

Article

TMFBiologyFool published an article 3:52 PM

Another Alzheimer's Disease Failure

Eli Lilly stops phase 2 trial of BACE inhibitor after some Alzheimer's patients had abnormal liver biochemical tests.

Article

TMFBiologyFool published an article 1:59 PM

Ovarian Cancer Drug Half Way There

Amgen's trebananib delays progression, but survival data is key.

Article

TMFBiologyFool published an article 12:59 PM

Why the Pfizer-Teva Settlement Affects the Whole Industy

Score one for the branded drugs.

Article

TMFBiologyFool published an article 4:16 PM

Drug Rejected! Let's Rejoice?

AVEO's shares go up on the FDA's rejection of tivozanib.

Article

TMFBiologyFool published an article 6:30 PM

New Obesity Drug Hits the Market

There's plenty of room for two drugs in an expanding market. Here's what investors need to know.

Article

TMFBiologyFool published an article 3:39 PM

Why You Should Care About This Diabetes Drug Saga

Are changes to Glaxo's Avandia a sign that the FDA is lightening up?

Article

TMFBiologyFool published an article 6:30 PM

This Pharma Is Trading Like a Biotech

Bristol-Myers zooms up on clinical trial data.

Article

TMFBiologyFool published an article 6:30 PM

Double Data, Double Stock Price

Clovis doubles on ASCO data for two of its drugs.

Article

TMFBiologyFool published an article 8:42 PM

ASCO Investment Ideas

The cancer meeting is upon us.

Article

TMFBiologyFool published an article 7:38 PM

3 Biotech Companies You Should Have Bought This Year

But are they still buys?

Article

TMFBiologyFool published an article 6:50 PM

Dividend Investor's Archnemesis

He's rearing his ugly head in the health-care space.

Article

TMFBiologyFool published an article 1:36 PM

Stocks to Buy: Biotechs With Binary Events

If you can tolerate the risk, they're the way to go.

Article

TMFBiologyFool published an article 1:36 PM

Stocks to Buy: Biotechs With Growth Potential

They're still risky though.

Article

TMFBiologyFool published an article 1:35 PM

Stocks to Buy: Value Biotechs

Value? Biotech? An oxymoron?

Article

TMFBiologyFool published an article 8:25 PM

Where to Invest for More Health-Care Exposure

There's something for everyone in the sector.

Article

TMFBiologyFool published an article 8:14 PM

Should You Trade Pfizer Stock for Shares in Zoetis?

An animal of a decision.

Article

TMFBiologyFool published an article 1:18 PM

Johnson & Johnson Stock Takes a Breather

After a 12-week run, Johnson & Johnson stock fell last week. Here's what investors should keep an eye on.